IP Library Granted Patent US 9,920,323
Granted Patent B2
US 9,920,323 · App. 13/178,402 · Granted Mar 20, 2018

Genetically modified phage and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,323
App. No.
13/178,402
Granted
Mar 20, 2018
Kind
B2
Abstract

The present invention relates to a genetically modified phage and use thereof in a method for producing a biomolecule of interest.

Claims (21)

1. A lambda phage, comprising the sequence of SEQ ID NO: 35 or a sequence that is at least 90% identical, wherein the lambda phage is modified by:

insertion of a T7 expression system; and

deletion of the S and R genes, wherein the S gene corresponds to SEQ ID NO:1 (wildtype S gene) or to a sequence which is at least 90% identical to SEQ ID NO: 1, wherein the R gene corresponds to SEQ ID NO:2 (wildtype R gene) or to a sequence which is at least 90% identical to SEQ ID NO: 2 and wherein the deletion of the S and R genes reduce the ability of the phage to regain its lytic properties.

2. The lambda phage of claim 1 , further comprising at least one deleted Int gene or deleted Xis gene; wherein the Int gene corresponds to SEQ ID NO:7 (wildtype Int gene) or to a sequence which is at least 90% identical to SEQ ID NO:7 wherein the Xis gene corresponds to SEQ ID NO:8 (wildtype Xis gene) or a sequence which is at least 90% identical to SEQ ID NO:8, and wherein the deletion of the Int and/or Xis gene reduces the ability of the phage to excise itself.

3. The lambda phage of claim 1 , further comprising at least one deleted Int gene, Xis gene or Rz gene wherein the Int gene corresponds to SEQ ID NO:7 (wildtype Int gene) or to a sequence which is at least 90% identical to SEQ ID NO:7, wherein the Xis gene corresponds to SEQ ID NO:8 (wildtype Xis gene) or a sequence which is at least 90% identical to SEQ ID NO:8, wherein the Rz gene corresponds to SEQ ID NO:3 (wildtype Rz gene) or a sequence which is at least 90% identical to SEQ ID NO:3, wherein the deletion of the Rz gene reduces the ability of the phage to regain its lytic properties, and wherein the deletion of the Int and/or Xis gene reduces the ability of the phage to excise itself.

4. The lambda phage of claim 1 , further comprising deleted Int gene, deleted Xis gene, and deleted Rz gene, wherein the Int gene corresponds to SEQ ID NO:7 (wildtype Int gene) or to a sequence which is at least 90% identical to SEQ ID NO:7, wherein the Xis gene corresponds to SEQ ID NO:8 (wildtype Xis gene) or a sequence which is at least 90% identical to SEQ ID NO:8, wherein the Rz gene corresponds to SEQ ID NO:3 (wildtype Rz gene) or a sequence which is at least 90% identical to SEQ ID NO:3, wherein the deletion of the Rz gene reduces the ability of the phage to regain its lytic properties, and wherein the deletion of the Int and Xis genes reduces the ability of the phage to excise itself.

5. The lambda phage of claim 1 , comprising a sequence of SEQ ID NO: 10.

6. A host cell comprising the lambda phage of claim 1 .

7. The host cell of claim 6 , wherein the lambda phage comprises at least one deleted Int gene, Xis gene or Rz gene, wherein the deletion of the Rz gene reduces the ability of the phage to regain its lytic properties, wherein the deletion of the Int and/or Xis gene reduces the ability of the phage to excise itself wherein the Int gene corresponds to SEQ ID NO:7 (wildtype Int gene) or to a sequence which is at least 90% identical to SEQ ID NO:7, wherein the Xis gene corresponds to SEQ ID NO:8 (wildtype Xis gene) or a sequence which is at least 90% identical to SEQ ID NO:8, and wherein the Rz gene corresponds to SEQ ID NO:3 (wildtype Rz gene) or a sequence which is at least 90% identical to SEQ ID NO:3.

8. The host cell of claim 6 , wherein the lambda phage comprises a deleted Int gene, deleted Xis gene, and deleted Rz gene, wherein the Int gene corresponds to SEQ ID NO:7 (wildtype Int gene) or to a sequence which is at least 90% identical to SEQ ID NO:7, wherein the Xis gene corresponds to SEQ ID NO:8 (wildtype Xis gene) or a sequence which is at least 90% identical to SEQ ID NO:8, wherein the Rz gene corresponds to SEQ ID NO:3 (wildtype Rz gene) or a sequence which is at least 90% identical to SEQ ID NO:3, wherein the deletion of the Rz gene reduces the ability of the phage to regain its lytic properties, and wherein the deletion of the Int and Xis genes reduces the ability of the phage to excise itself.

9. The host cell of claim 6 , wherein the lambda phage comprises a sequence of SEQ ID NO: 10.

10. The host cell of claim 6 , wherein the host cell is an enterobacteria.

11. The host cell of claim 10 , wherein the enterobacteria is Escherichia coli.

12. The host cell of claim 6 , further comprising at least one inactivated tonA, galK, araB, araA, ion, ompT, rcsA, hsdR, mrr, endA, or recA gene.

13. The host cell of claim 6 , comprising an inserted ccdb gene.

14. A process for preparing the host cell of claim 6 , comprising infecting the host cell with a lambda phage comprising the sequence of SEQ ID NO: 35 or a sequence that is at least 90% identical to SEQ ID NO: 35,

wherein the lambda phage is modified by:

insertion of a T7 expression system; and

deletion of the S and R genes, wherein the S gene corresponds to SEQ ID NO:1 (wildtype S gene) or to a sequence which is at least 90% identical to SEQ ID NO: 1 wherein the R gene corresponds to SEQ ID NO:2 (wildtype R gene) or to a sequence which is at least 90% identical to SEQ ID NO: 2, and

wherein the deletion of the S and R genes reduces the ability of the phage to regain its lytic properties.

15. The lambda phage of claim 1 , wherein the lambda phage further comprises a T7 RNA polymerase.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: DELPHI GENETICS
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 056673/0745 →